What is the JAK2 mutation?

The video and the infographic below demonstrate the effect of the Janus-kinase 2 (JAK2) V617F mutation in some individuals with Essential Thrombocythemia (ET). This mutation leads to constitutive activation of JAK-STAT signaling pathway which controls the transcription of many genes responsible for survival, proliferation and migration.

Share this page to spread the awareness of MPN and Essential Thrombocythemia.


Watch Professor Skoda’s webinar to discover which other genetic mutations can impact myeloproliferative neoplasms.

Take the challenge and see if you can diagnose Emma, the virtual patient case.

back to top